Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), was developed as an antihyperglycemic agent and has been shown to improve multiple health outcomes for patients with type 2 diabetes mellitus (T2DM). The gene discussed is GLP1R; the disease is diabetes mellitus.